How to buy BioAtla stock | $43.05

San Diego-based BioAtla, a company that produces cancer therapies, wrapped its initial public offering.

BioAtla stock price (NASDAQ: BCAB)

Use our graph to track the performance of BCAB stocks over time.

BioAtla shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$43.05
52-week range	$27.15 - $76.63
50-day moving average	$41.54
200-day moving average	$47.67
Wall St. target price	$76.25
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy BioAtla shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy BioAtla stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of BioAtla, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BioAtla price performance over time

Historical closes compared with the close of $43.05 from 2021-05-28

1 week (2021-07-23)	N/A
1 month (2021-07-02)	-1.40%
3 months (2021-05-03)	-8.11%
6 months (2021-01-30)	N/A

1 year (2020-07-30)	N/A
2 years (2019-07-30)	N/A
3 years (2018-07-30)	N/A
5 years (2016-07-30)	N/A

BioAtla financials

Revenue TTM	$340,000
Gross profit TTM	$-19,504,000
Return on assets TTM	-14.8%
Return on equity TTM	-46.57%
Profit margin	0%
Book value	$5.82
Market capitalisation	$1.3 billion

TTM: trailing 12 months

Shorting BioAtla shares

There are currently 3.3 million BioAtla shares held short by investors – that's known as BioAtla's "short interest". This figure is 0.4% up from 3.3 million last month.

There are a few different ways that this level of interest in shorting BioAtla shares can be evaluated.

BioAtla's "short interest ratio" (SIR)

BioAtla's "short interest ratio" (SIR) is the quantity of BioAtla shares currently shorted divided by the average quantity of BioAtla shares traded daily (recently around 327624.90118577). BioAtla's SIR currently stands at 10.12. In other words for every 100,000 BioAtla shares traded daily on the market, roughly 10120 shares are currently held short.

To gain some more context, you can compare BioAtla's short interest ratio against those of similar companies.

• XBiotech (XBIT.US): 5.52
• Genmab A/S (GMAB.US): 2.33
• Mersana Therapeutics (MRSN.US): 10.43

However BioAtla's short interest can also be evaluated against the total number of BioAtla shares, or, against the total number of tradable BioAtla shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioAtla's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 BioAtla shares in existence, roughly 100 shares are currently held short) or 0.1778% of the tradable shares (for every 100,000 tradable BioAtla shares, roughly 178 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against BioAtla.

Find out more about how you can short BioAtla stock.

BioAtla share dividends

We're not expecting BioAtla to pay a dividend over the next 12 months.

BioAtla overview

BioAtla, Inc. , a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California. .

Frequently asked questions

What percentage of BioAtla is owned by insiders or institutions?
Currently 16.418% of BioAtla shares are held by insiders and 58.807% by institutions. How many people work for BioAtla?
Latest data suggests 36 work at BioAtla. When does the fiscal year end for BioAtla?
BioAtla's fiscal year ends in December. Where is BioAtla based?
BioAtla's address is: 11085 Torreyana Road, San Diego, CA, United States, 92121